Daiwa Securities Group Inc. acquired a new position in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 43,097 shares of the company’s stock, valued at approximately $67,000.
Several other large investors also recently added to or reduced their stakes in OCGN. Bank of New York Mellon Corp increased its stake in Ocugen by 2,760.5% during the second quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock worth $1,165,000 after acquiring an additional 725,536 shares during the last quarter. Rhumbline Advisers increased its stake in Ocugen by 3,040.0% during the second quarter. Rhumbline Advisers now owns 301,218 shares of the company’s stock worth $467,000 after acquiring an additional 291,625 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Ocugen during the first quarter valued at approximately $132,000. Tidal Investments LLC bought a new position in shares of Ocugen during the first quarter valued at approximately $108,000. Finally, Headlands Technologies LLC bought a new position in shares of Ocugen during the first quarter valued at approximately $66,000. 10.27% of the stock is owned by institutional investors.
Ocugen Trading Down 4.3 %
OCGN opened at $1.12 on Wednesday. The stock has a market cap of $288.24 million, a price-to-earnings ratio of -4.48 and a beta of 3.69. The stock’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.46. Ocugen, Inc. has a one year low of $0.35 and a one year high of $2.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.04 and a current ratio of 1.04.
Ocugen Company Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Read More
- Five stocks we like better than Ocugen
- Why Invest in 5G? How to Invest in 5G Stocks
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How to Use the MarketBeat Excel Dividend Calculator
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- How to Invest in the Best Canadian Stocks
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding OCGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocugen, Inc. (NASDAQ:OCGN – Free Report).
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.